TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12085418
Drug: Losartan/Hydrochlorothiazide 20/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/Hydrochlorothiazide 20/12.5 mg/day (LH)
Study: 9593032
Drug: Trivalent cold-adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent cold-adapted influenza vaccine (CAIV-T) at high dose
Study: 9593032
Drug: Trivalent cold-adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent cold-adapted influenza vaccine (CAIV-T) at low dose
Study: 9593032
Drug: Trivalent cold-adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent cold-adapted influenza vaccine (CAIV-T) administered by drops
Study: 9593032
Drug: Trivalent cold-adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent cold-adapted influenza vaccine (CAIV-T) administered by spray
Study: 7551834
Drug: Control (ECOG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (ECOG chemotherapy protocols)
Study: 2230272
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination (polymyxin, gentamicin, and nystatin as oral paste and solution)
Study: 31959235
Drug: MS Stay
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS Stay Fit (two booster sessions at 2 and 4 months after end of treatment)
Study: 28556449
Drug: 2.4 mg
Normalized name: pectin 2.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg beloranib
Study: 17195608
Drug: Interventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional management (medical treatment, early coronarography, revascularization)
Study: 14624703
Drug: Baclofen (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (60 mg/day)
Study: 7523739
Drug: Methotrexate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (50 mg/m²) + Misoprostol (800 mcg)
Study: 7523739
Drug: Misoprostol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (800 mcg) alone
Study: 3366415
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg dose of trans-anethole
Study: 3366415
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dose of trans-anethole
Study: 3366415
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg dose of trans-anethole
Study: 25286691
Drug: Injectable cefetamet
Normalized name: cefetamet
DrugBank: Cefetamet (DB13504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable cefetamet sodium (500 mg, 1,000 mg, 2,000 mg)
Study: 25286691
Drug: Injectable cefetamet
Normalized name: cefetamet
DrugBank: Cefetamet (DB13504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable cefetamet sodium (500 mg)
Study: 25286691
Drug: Injectable cefetamet
Normalized name: cefetamet
DrugBank: Cefetamet (DB13504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable cefetamet sodium (1,000 mg)
Study: 25286691
Drug: Injectable cefetamet
Normalized name: cefetamet
DrugBank: Cefetamet (DB13504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable cefetamet sodium (2,000 mg)
Study: 19298635
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 μg once daily in the morning
Study: 18199095
Drug: Intravenous L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine supplementation
Study: 16050414
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II blockers
Study: 16050414
Drug: Concomitant use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant use of statins and angiotensin II blockers
Study: 11520725
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen (2 L/min)
Study: 7031982
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin fraction
Study: 7031982
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight heparin fraction
Study: 7031982
Drug: All heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: All heparin preparations
Study: 25765966
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of ProQuad(®) and hexavalent vaccine
Study: 25765966
Drug: Hexavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent vaccine alone
Study: 11320361
Drug: Accelerated TPA
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated TPA with reduced heparin dose mid-trial
Study: 11320361
Drug: Accelerated TPA
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated TPA with lowest heparin dose
Study: 11320361
Drug: Single-bolus TNK-TPA
Normalized name: TNK-tPA
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-bolus TNK-TPA and lanoteplase with reduced heparin dose
Study: 11320361
Drug: Lower-dose, weight-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose, weight-adjusted heparin regimen (60 U/kg bolus; maximum, 4000 U; 12 U/kg per hour infusion; maximum, 1000 U/h)
Study: 9447478
Drug: Thiothixene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiothixene (20 mg single oral dose)
Study: 28902705
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (120,000 IU/monthly)
Study: 28902705
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose vitamin D (60,000 IU/monthly)
Study: 28902705
Drug: Standard/control dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard/control dose vitamin D (18,000 IU/monthly)
Study: 26303780
Drug: MFGM (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFGM (1 g)
Study: 24030722
Drug: Campaign materials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campaign materials (mainly posters, brochures, and advertisements on local media, plus a newsletter on local antibiotic resistance targeted at doctors and pharmacists)
Study: 21132310
Drug: Intracoronary pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary pyruvate (300 mmol/L, 360 ml/h)
Study: 18300256
Drug: Docetaxel every
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel every 3 weeks (75 mg/m2)
Study: 18300256
Drug: Docetaxel weekly
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel weekly (35 mg/m2)
Study: 6532147
Drug: Alcohol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.6 g of ethanol per kg of body weight)
Study: 6532147
Drug: Non-alcohol treatments
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-alcohol treatments
Study: 26285178
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg followed by misoprostol 800 mcg vaginally 6-8 or 23-25 hours later
Study: 26285178
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg followed by misoprostol 800 mcg vaginally < 15 min or 23-25 hours later
Study: 15653703
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) 4 g/m² followed by leucovorin rescue
Study: 7719244
Drug: Various biologic
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various biologic and chemotherapeutic agents for hairy-cell leukemia
Study: 2692651
Drug: Weekly 20
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly 20 mg doses of doxorubicin
Study: 25440999
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg orally once a day for 12 weeks
Study: 25440999
Drug: Lisinopril 5
Normalized name: lisinopril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5 mg orally once a day for 12 weeks
Study: 25440999
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between telmisartan and lisinopril
Study: 16500321
Drug: Cetrorelix (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix (0.25 mg SC) with half dose of recombinant FSH for 2 days until hCG administration
Study: 16500321
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 32) continued recombinant FSH until hCG administration
Study: 12795584
Drug: Behavioral day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral day treatment plus abstinence-contingent housing and work therapy
Study: 12795584
Drug: Behavioral day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral day treatment only
Study: 10856892
Drug: Intravenous TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TRH administration
Study: 10856892
Drug: Nasal TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal TRH administration
Study: 10856892
Drug: Oral TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TRH administration
Study: 9168167
Drug: Clonazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (1 mg for 1 day)
Study: 9168167
Drug: Vigabatrin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (1000 mg per day for 5 days)
Study: 3510282
Drug: Continuous cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous cyclic therapy with dibromodulcitol, doxorubicin, vincristine, tamoxifen, and fluoxymesterone (DAVTH)
Study: 3510282
Drug: Serial CEA
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial CEA levels during therapy
Study: 3510282
Drug: Continuous DAVTH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous DAVTH therapy
Study: 24884602
Drug: Canakinumab low
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab low dose (0.03 mg/kg i.v. once, N = 20)
Study: 24884602
Drug: Canakinumab intermediate
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab intermediate dose (0.1 and 0.3 mg/kg i.v. once, 5 and 15 mg s.c. monthly, N = 247)
Study: 24884602
Drug: Canakinumab medium
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab medium dose (1.5 mg/kg i.v. once, 50 mg s.c. monthly and 150 mg s.c. once, N = 268)
Study: 24884602
Drug: Canakinumab high
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab high dose (10 mg/kg i.v. once and 150 mg s.c. monthly, N = 137)
Study: 23102995
Drug: Olmesartan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan plus Calcium Channel Blocker (CCB)
Study: 23102995
Drug: Olmesartan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan plus Diuretic
Study: 1828408
Drug: Esaprazole (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaprazole (450 mg bid)
Study: 1828408
Drug: Sulglicotide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulglicotide (200 mg tid)
Study: 7014284
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg i.m. domperidone
Study: 7014284
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg t.i.d. domperidone
Study: 28389389
Drug: Capsaicin nasal
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin nasal spray
Study: 26010860
Drug: Paroxetine 20mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20mg/day for 6 weeks, with dose escalation up to 50mg/day for non-responders
Study: 21300339
Drug: Depot leuprolide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot leuprolide, 11.25 mg IM every 12 weeks with hormonal add-back using norethindrone acetate 5 mg orally, daily
Study: 21300339
Drug: Generic monophasic
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic monophasic oral contraceptive (1 mg norethindrone + 35 mg ethinyl estradiol) given daily
Study: 11416677
Drug: candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: candesartan cilexetil 16 mg once daily, increased to 32 mg after 2 weeks
Study: 11416677
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg once daily, increased to 100 mg after 2 weeks
Study: 9293650
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 0.125% bupivacaine (with 1/200,000 epinephrine)
Study: 9293650
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of isotonic saline (with 1/200,000 epinephrine)
Study: 8447520
Drug: Low clearing
Normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low clearing doses of ivermectin followed by 200-400 micrograms/kg of ivermectin
Study: 8447520
Drug: 6 or
Normalized name: Serc-16 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 or 7 mg/kg of DEC
Study: 8447520
Drug: Clearing dose
Normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clearing dose of ivermectin followed by 6 mg/kg of DEC
Study: 3768248
Drug: Theophylline preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline preparation with ethylenediamine
Study: 3768248
Drug: Theophylline preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline preparation with sodium glycinate
Study: 29696963
Drug: Metoprolol (on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (on the basis of aspirin)
Study: 23365129
Drug: Cinacalcet and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet and low-dose vitamin D sterols (Cin-D)
Study: 23365129
Drug: Larger, varying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger, varying doses of calcitriol or other vitamin D analogs (Flex-D)
Study: 20601929
Drug: Expedited partner
Normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedited partner therapy (EPT)
Study: 16422889
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch (5 mg/day applied at 2200 h)
Study: 16422889
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (5 g/day applied at 0800 h)
Study: 12835492
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg/d) for 14 weeks followed by copper supplementation (3 mg/d) for 8 weeks
Study: 12835492
Drug: Placebo supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplements for the full duration of the trial
Study: 1387041
Drug: Oral terfenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terfenadine (120 mg)
Study: 1387041
Drug: Oral terfenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terfenadine (120 mg) and nasal ipratropium bromide (80 micrograms)
Study: 6437102
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg levonorgestrel per coitus
Study: 6437102
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg levonorgestrel per coitus
Study: 6437102
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of levonorgestrel
Study: 24670520
Drug: protease inhibitor+RTV+two
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: protease inhibitor+RTV+two NRTIs
Study: 23158423
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (35 ml contrast medium)
Study: 23158423
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (40 ml contrast medium)
Study: 23158423
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (45 ml contrast medium)
Study: 23158423
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (50 ml contrast medium)
Study: 19022318
Drug: Low-dose intradermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intradermal injection (3 microg hemagglutinin per strain) using MicronJet (ID1 group)
Study: 19022318
Drug: Medium-dose intradermal
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose intradermal injection (6 microg hemagglutinin per strain) using MicronJet (ID2 group)
Study: 19022318
Drug: Full-dose standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose standard flu shot (15 microg hemagglutinin per strain) delivered intramuscularly (IM group)
Study: 2574193
Drug: Diazepam (N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (N = 21; mean diazepam dose equivalents, 15 mg/day; range, 5‐40)
Study: 28665371
Drug: mexidol: 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: mexidol: 500 mg/day IV infusion for 10 days, followed by 125 mg tid (375 mg/day) PO for 8 weeks
Study: 23457387
Drug: Golimumab (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (combined 50 mg + MTX or 100 mg ± MTX), n = 115
Study: 12117291
Drug: Heparin rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin rinse at 2,000 IU/L
Study: 12117291
Drug: Heparin rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin rinse at 10,000 IU/L
Study: 30898822
Drug: Belimumab SC
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab SC 200 mg/week for 52 weeks plus placebo at weeks 4 and 6
Study: 30898822
Drug: Belimumab SC
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab SC 200 mg/week for 52 weeks plus rituximab 1000 mg at weeks 4 and 6
Study: 30898822
Drug: Belimumab SC
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab SC 200 mg/week plus standard of care for 104 weeks
Study: 25477424
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg 6R‐BH4 twice daily + 1 mg folic acid once daily
Study: 24147622
Drug: Deferasirox (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (20 mg/kg/day, titrated to 5-10 mg/kg/day based on serum ferritin trends)
Study: 24147622
Drug: Deferasirox (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (mean actual dose 33.6 mg/kg/day in 1-year extension)
Study: 19517675
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anaesthesia (group B, n=27, 0.5% hyperbaric bupivacaine, 1.2 mL + 0.1 mL per every 10 cm over 170 cm height)
Study: 19517675
Drug: Bilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral spinal anaesthesia (group K, n=27, 0.5% bupivacaine 2.4 mL + 0.2 mL per every 10 cm over 170 cm height)
Study: 11287776
Drug: Pyridoxine 50
Normalized name: pyridoxine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine 50 mg/day
Study: 7999470
Drug: Individual screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual screening prescriptions based on risk
Study: 24131167
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch + nicotine nasal spray
Study: 24131167
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch + placebo nasal spray
Study: 21112774
Drug: Chemoradiotherapy (CRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (CRT) with cisplatin (100mg/m(2) for three cycles) plus adjuvant cisplatin (80 mg/m(2)) and fluorouracil (1000 mg/m(2)/day for 4 days for three cycles)
Study: 21112774
Drug: Cisplatin during
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin during concurrent phase
Study: 21112774
Drug: Concurrent cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent cycles of cisplatin
Study: 12657406
Drug: Aprotinin (1,000,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (1,000,000 KIU loading dose, followed by an infusion of 250,000 KIU/hr)
Study: 10755072
Drug: Gold-standard definition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold-standard definition of treatment superiority with unpublished scales
Study: 1313717
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg o.d.
Study: 1313717
Drug: Griseofulvin 500
Normalized name: griseofulvin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 500 mg o.d.
Study: 1313717
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg daily for 15 days (tinea corporis/cruris) and 30 days (tinea pedis/manus).
Study: 1313717
Drug: Griseofulvin 500
Normalized name: griseofulvin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 500 mg ultramicronized daily for 15 days (tinea corporis/cruris) and 30 days (tinea pedis/manus).
Study: 1313717
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg daily.
Study: 1313717
Drug: Griseofulvin 500
Normalized name: griseofulvin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 500 mg daily.
Study: 26088405
Drug: High-dose dimethylfumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dimethylfumarate (DMF)
Study: 25232107
Drug: Serotonin modulation
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin modulation through pharmaceutical intervention
Study: 17093981
Drug: Atomoxetine (max
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (max 1.8 mg/kg/day, daily) for 6-8 weeks
Study: 8576747
Drug: Pulsatile oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile oxytocin administration (boluses every 8 minutes)